Trevi Therapeutics, Inc. TRVI Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s stock issuance proceeds?
- Trevi Therapeutics, Inc. (TRVI) reported stock issuance proceeds of $222K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Trevi Therapeutics, Inc.'s stock issuance proceeds decreased by 69.1% year-over-year, from $718K to $222K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s stock issuance proceeds?
- Over 3 years (2022 to 2025), Trevi Therapeutics, Inc.'s stock issuance proceeds has grown at a 111.3% compound annual growth rate (CAGR), from $220.25K to $2.08M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.